The G-Men Cometh
The United States Federal Trade Commision promises to hold gender gangsters to account
On Wednesday July 9th, parents, detransitioners, clinicians, legal professionals, and others gathered with the Federal Trade Commission (FTC) in Washington, DC, for an all-day workshop on “The Dangers of ‘Gender-Affirming Care’ for Minors.” Nestled deep in the Congressional Center, the event lacked the fanfare of a legislative hearing or the pomp of the West Wing, but it felt portentous. Why? Because, while many of us have understood from the beginning that trans medical procedures are harmful, it appears that they are also illegal under existing consumer protection laws. Now, under the auspices of the Trump Administration, the FTC is set to exercise its authority under Section 5 of the FTC Act to investigate deceptive claims about the safety and necessity of puberty blockers, hormones, and surgeries
.
The Federal Trade Commission (FTC) is an independent agency of the U.S. government that focuses on protecting consumers from fraud. Through a combination of antitrust enforcement (preventing monopolies and other unfair modes of operation) and guarding the public against fraudulent, deceptive, and unfair business practices, they are the government men and women, or “G-Men,” who, when empowered to act, tirelessly champion ordinary citizens, safeguarding the little guy against corporate greed and organized deceit.
There was a palpable sense of relief in the room when Andrew N. Ferguson, Chairman, Federal Trade Commission, took the stage. He began by recounting how the Biden administration pressured the World Professional Association for Transgender Health (WPATH) to remove age-minimum requirements for cross-sex hormones and other sex-change surgeries from their Standards of Care 8 guidelines on care of transgender youth. “The Biden Administration’s concern,” he explained, “was not that age-minimum requirements were unscientific, unreasonable, or unhelpful to doctors, therapists, parents, and children experiencing gender dysphoria.” Science wasn’t the point. They worried that “age-minimum requirements gave too much ammunition to critics of ‘gender-affirming care.’”
He went on:
Today is not about politics. It is about the parents and kids the Biden administration chose to ignore. It is about our nation’s children, who stand in most need of our love, protection, and support. It is about their parents, whose selfless and fruitful love is the foundation of our nation and every nation. It is about caring for the most vulnerable among us and protecting them from manipulation and abuse. It is about healing the wounds that proponents of gender-affirming care may have inflicted on our nation’s children and parents and preventing the potential for future harm. Today is going to be about people, not politics.
There’s a New Sheriff in Town
This moment has been a long time coming for the parents of children who were asked by the clinicians they trusted, “Would you rather have a live son or a dead daughter?” And for the medical professionals and scientists who knew that the claims being made weren’t adding up; for the whistleblowers who paid the price for exposing their employer’s fraud; for the lawyers who stepped back from lucrative practices to take on the lawsuits of the people harmed by puberty blockers, cross-sex hormones, and surgeries. Most of all, it was a significant moment for the detransitioners who live with the grave consequences of the experimental medical procedures they received in the name of identity affirmation. Many of the individual stories shared were familiar.
There was Prisha Mosley, the detransitioned woman who suffered excruciating pain when the remnants of her breast tissue from a “gender-affirming” mastectomy began producing milk within her chest after she gave birth; Claire Abernathy, whose breasts were removed in the summer after her 8th grade graduation; Soren Aldaco, who was prescribed testosterone after a short appointment; Elvira Syed, the mother whose medically transitioned daughter’s body lay undiscovered for days in her college dorm room after she committed suicide, while her dorm mates celebrated “Coming Out Day.” The horror of their experiences is not new. Even so, there were many moments when the audience, most of them veterans in the struggle against gender quackery, gasped at some of the details. The difference now is that the G-men are firmly on the case.
The Untouchables
Much like the IRS’s game-changing pursuit of mobster Al Capone for tax evasion in the 1930s, when his violent crimes proved untouchable, the FTC is leveraging its authority to investigate deceptive claims about the safety and necessity of puberty blockers, hormones, and surgeries. Chairman Ferguson compared purveyors of so-called “gender-affirming care” to the snake oil salesmen of old who exploited the desperation and pain of vulnerable people for financial gain.
Not only does the FTC have jurisdiction in this area—the FTC has brought dozens of enforcement actions against false and misleading health claims by pharmaceutical companies, manufacturers of supplements, and clinics purveying unproven treatments like stem cell therapies—but “it is the Commission’s duty to protect American citizens” from potential consumer harm.
Confronting Big Gender
The event was an opportunity to reflect on the last decade, during which gender practitioners and ideologues have been allowed to run wild. Dr. Miriam Grossman began the workshops by speaking on the dangerous normalization of language, in terms like “sex assigned at birth” or “gender-affirming care,” and the potentially deadly obfuscation of sex in health care settings.
Then it was on to the panel on the corruption of science, where we learned about how safeguards like peer review and the declaration of conflicts of interest have been compromised. Circular citations and unpublished systematic reviews are just the tip of the iceberg. Leor Sapir spoke about the broken chain of trust and argued that the people who least deserve blame for the harms inflicted by the gender industry are the parents and medical professionals who assumed good faith on the part of so-called experts.
Other highlights included:
The panel of whistleblowers who described how and why they pushed back when asked to transition minors and the price they paid for speaking out.
The final eye-opening panel, which identified key areas in which the FTC should act, such as holding medical associations to account for deceptive claims and guidelines, and other creative tactics, such as educating the judiciary on the deficiencies of the guidelines they have deferred to.
Genspect board member Erin Friday’s (a.k.a. Erin: Warrior Queen) inventory and rogues’ gallery of the worst offenders in the Gender Industry. (below)
Watch the workshop here
How You Can Help
The Commission intends to issue a public request for information on the various topics covered in the workshop. Inspecting Gender will share the details when they become available — and we will be sharing what we have learned in the course of our work.
A New Era Begins
Join Genspect at The Bigger Picture conference in Albuquerque, New Mexico, September 27–28, 2025, where we’ll explore the implications of the new climate around gender in the United States, what we’ve learned and what we need to do now. Register now at genspect.org
Tickets selling fast - secure your seat now.
For years, gender-critical voices have faced a relentless campaign of suppression. Trans activists have repeatedly sought to deprive critics of gender ideology of the most basic democratic freedoms—expression and assembly—through intimidation, threats, venue cancellations, and disruptions. Peaceful events have been shouted down, protestors have blocked access, and some speakers have been physically assaulted. Meanwhile, official bodies—ranging from medical associations to human rights commissions—have too often been captured by ideologically aligned insiders who refuse to engage with evidence that challenges their affirming orthodoxy.
That’s what makes the FTC workshop so significant. At last, there is a venue where the harms of “gender-affirming care” can be addressed with seriousness and without interruption. No one was silenced, shouted down, or deplatformed. This was not just a policy discussion—it was a democratic breakthrough. For the first time in years, those most affected by this medical scandal were able to make their case to federal authorities on equal footing, free from the performative theatrics and institutional bias that have so often poisoned this conversation.